Anti-tumor Drug Market Report – Research, Industry Analysis Reports and Market Demands

Global Anti-tumor Drug Market Growth (Status and Outlook) 2019-2024

Request for Sample of this report

Buy now

Table of Content

2019-2024 Global Anti-tumor Drug Market Report (Status and Outlook)

1 Scope of the Report

2 Executive Summary

2.1 World Market Overview
- 2.1.1 Global Anti-tumor Drug Market Size 2014-2024
- 2.1.2 Anti-tumor Drug Market Size CAGR by Region
2.2 Anti-tumor Drug Segment by Type
- 2.2.1 Cytotoxic Drugs
- 2.2.2 Non-cytotoxic Drugs
2.3 Anti-tumor Drug Market Size by Type
- 2.3.1 Global Anti-tumor Drug Market Size Market Share by Type (2014-2019)
- 2.3.2 Global Anti-tumor Drug Market Size Growth Rate by Type (2014-2019)
2.4 Anti-tumor Drug Segment by Application
- 2.4.1 Alkylating Agents
- 2.4.2 Anti-metabolism Drugs
- 2.4.3 Platinum Antineoplastic Agents
- 2.4.4 Anthracycline antitumor drugs
- 2.4.5 Microtubule Stabilizer
- 2.4.6 Endocrine Therapy Drugs
- 2.4.7 Immunotherapy Drugs
- 2.4.8 Gene Therapy Drugs
- 2.4.9 Targeted Antineoplastic Drugs
2.5 Anti-tumor Drug Market Size by Application
- 2.5.1 Global Anti-tumor Drug Market Size Market Share by Application (2014-2019)
- 2.5.2 Global Anti-tumor Drug Market Size Growth Rate by Application (2014-2019)

3 Global Anti-tumor Drug by Players

3.1 Global Anti-tumor Drug Market Size Market Share by Players
- 3.1.1 Global Anti-tumor Drug Market Size by Players (2017-2019)
- 3.1.2 Global Anti-tumor Drug Market Size Market Share by Players (2017-2019)
3.2 Global Anti-tumor Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 Anti-tumor Drug by Regions

4.1 Anti-tumor Drug Market Size by Regions
4.2 Americas Anti-tumor Drug Market Size Growth
4.3 APAC Anti-tumor Drug Market Size Growth
4.4 Europe Anti-tumor Drug Market Size Growth
4.5 Middle East & Africa Anti-tumor Drug Market Size Growth

5 Americas

5.1 Americas Anti-tumor Drug Market Size by Countries
5.2 Americas Anti-tumor Drug Market Size by Type
5.3 Americas Anti-tumor Drug Market Size by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Key Economic Indicators of Few Americas Countries

6 APAC

6.1 APAC Anti-tumor Drug Market Size by Countries
6.2 APAC Anti-tumor Drug Market Size by Type
6.3 APAC Anti-tumor Drug Market Size by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Countries

7 Europe

7.1 Europe Anti-tumor Drug by Countries
7.2 Europe Anti-tumor Drug Market Size by Type
7.3 Europe Anti-tumor Drug Market Size by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

8.1 Middle East & Africa Anti-tumor Drug by Countries
8.2 Middle East & Africa Anti-tumor Drug Market Size by Type
8.3 Middle East & Africa Anti-tumor Drug Market Size by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers and Impact
- 9.1.1 Growing Demand from Key Regions
- 9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Global Anti-tumor Drug Market Forecast

10.1 Global Anti-tumor Drug Market Size Forecast (2019-2024)
10.2 Global Anti-tumor Drug Forecast by Regions
- 10.2.1 Global Anti-tumor Drug Forecast by Regions (2019-2024)
- 10.2.2 Americas Market Forecast
- 10.2.3 APAC Market Forecast
- 10.2.4 Europe Market Forecast
- 10.2.5 Middle East & Africa Market Forecast
10.3 Americas Forecast by Countries
- 10.3.1 United States Market Forecast
- 10.3.2 Canada Market Forecast
- 10.3.3 Mexico Market Forecast
- 10.3.4 Brazil Market Forecast
10.4 APAC Forecast by Countries
- 10.4.1 China Market Forecast
- 10.4.2 Japan Market Forecast
- 10.4.3 Korea Market Forecast
- 10.4.4 Southeast Asia Market Forecast
- 10.4.5 India Market Forecast
- 10.4.6 Australia Market Forecast
10.5 Europe Forecast by Countries
- 10.5.1 Germany Market Forecast
- 10.5.2 France Market Forecast
- 10.5.3 UK Market Forecast
- 10.5.4 Italy Market Forecast
- 10.5.5 Russia Market Forecast
- 10.5.6 Spain Market Forecast
10.6 Middle East & Africa Forecast by Countries
- 10.6.1 Egypt Market Forecast
- 10.6.2 South Africa Market Forecast
- 10.6.3 Israel Market Forecast
- 10.6.4 Turkey Market Forecast
- 10.6.5 GCC Countries Market Forecast
10.7 Global Anti-tumor Drug Forecast by Type
10.8 Global Anti-tumor Drug Forecast by Application

11 Key Players Analysis

12 Research Findings and Conclusion

Description

Anti-tumor drugs are for the treatment of cancer diseases. In recent years, the development of molecular oncology and molecular pharmacology has gradually clarified the nature of the tumor. The invention and application of advanced technologies such as large-scale rapid screening, combinatorial chemistry and genetic engineering have accelerated the process of drug development. The research and development of anti-tumor drugs have been into a new era.
In China, antitumor drugs are also the key areas of concern for many enterprises. Such as Jiangsu Hengrui, Qilu Pharmaceutical and other well-known domestic enterprises in the anti-tumor drugs have invested a lot of money, there are many innovative anti-cancer drugs into the clinical research stage. In the meantime, there has been "explosive" growth in the development of molecularly targeted drugs, with at least hundreds of drugs under development, and it is conceivable that the market will be quite crowded in the next five to 10 years. Therefore, domestic enterprises should fully understand the feasibility of the project and the fierce market competition that they may face in the future.
China's bio-pharmaceutical industry already has a good foundation; from the national level to local governments at all levels continue to step up efforts to support the development of bio-pharmaceutical industry. The output value of the pharmaceutical industry maintained a growth rate of 20% during the 12th Five-Year Plan period. In 2013, the total output value of the pharmaceutical industry reached 2.1 trillion yuan. However, compared with the bio-pharmaceutical industry in the advanced countries in the world, there is still a huge gap between the biomedical industry in our country and the demand for building an overall well-to-do society. Mainly manifested in: small-scale enterprises, more than 10 billion yuan enterprises and more than one billion yuan less; independent innovation ability is weak, many varieties of imitation with independent intellectual property rights of the few species; restrict some of the long-term development of biomedical industry , Deep-seated problems still exist.

According to this study, over the next five years the Anti-tumor Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Anti-tumor Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Anti-tumor Drug market by product type, application, key companies and key regions.

This study considers the Anti-tumor Drug value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Cytotoxic Drugs
Non-cytotoxic Drugs
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Alkylating Agents
Anti-metabolism Drugs
Platinum Antineoplastic Agents
Anthracycline antitumor drugs
Microtubule Stabilizer
Endocrine Therapy Drugs
Immunotherapy Drugs
Gene Therapy Drugs
Targeted Antineoplastic Drugs

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Novartis
Celgene
Bristol-Myers Squibb
Amgen
Johnson & Johnson
Pfizer
Takeda
Eli Lilly
AstraZeneca
Astellas
Merck & Co
Sanofi
Bayer
Biogen Idec
Eisai
Teva
Otsuka

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Anti-tumor Drug market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Anti-tumor Drug market by identifying its various subsegments.
Focuses on the key global Anti-tumor Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Anti-tumor Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Anti-tumor Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.